Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours

Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences

“…while 0V-TLI6 was produced independently, using a completely different procedure by immunization with cyst fiuid from a pooriy differentiated ovarian carcinoma [9]. Both antibodies are of the IgGl subtype, and have been shown to have similar binding characteristics [10]. The affinity constants of both antibodies are virtually identical (approximately l-l-l 4x 10^ M"').…”

“…The following MoAbs directed to ovarian carcinomaassociated antigens were used: OV-TL3 [2], 0V-TL16 [9]. OV-TL30 [10] and M0vl8 [12]; kindly supplied by Dr M. Colnaghi (National Cancer Institute. Milan.…”

Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences

“…while 0V-TLI6 was produced independently, using a completely different procedure by immunization with cyst fiuid from a pooriy differentiated ovarian carcinoma [9]. Both antibodies are of the IgGl subtype, and have been shown to have similar binding characteristics [10]. The affinity constants of both antibodies are virtually identical (approximately l-l-l 4x 10^ M"').…”

“…The following MoAbs directed to ovarian carcinomaassociated antigens were used: OV-TL3 [2], 0V-TL16 [9]. OV-TL30 [10] and M0vl8 [12]; kindly supplied by Dr M. Colnaghi (National Cancer Institute. Milan.…”

Use of Serum Tumor Markers in the Differential Diagnosis between Ovarian and Colorectal Adenocarcinomas

“…Efforts have been made to discriminate malignant from benign pelvic masses using monoclonal antibody-based tumor marker as says in serum [14][15][16][17][18][19] and in cyst fluid [20]. In general, elevated CA 125 serum levels are suggestive of malignancy.…”

Ovarian Carcinomas Express a Sperm Acrosomal Antigen, Defined by Monoclonal Antibody 9H8

“…9H8 dif fers from the others on the basis of a different expression pattern in normal tissues and mo lecular characteristics. The data available in the literature concerning 29 different anti bodies against ovarian carcinoma described by eight groups of authors [2][3][4][5][6][8][9][10] are dis cordant from 9H8 in respect of their reactivi ties with normal tissues. As all of these MAbs were confirmed to be unreactive with testis or fetal skin, we can conclude that the 9H8 anti gen is distinct from antigens described by the aforementioned authors.…”

Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences

“…while 0V-TLI6 was produced independently, using a completely different procedure by immunization with cyst fiuid from a pooriy differentiated ovarian carcinoma [9]. Both antibodies are of the IgGl subtype, and have been shown to have similar binding characteristics [10]. The affinity constants of both antibodies are virtually identical (approximately l-l-l 4x 10^ M"').…”

“…The following MoAbs directed to ovarian carcinomaassociated antigens were used: OV-TL3 [2], 0V-TL16 [9]. OV-TL30 [10] and M0vl8 [12]; kindly supplied by Dr M. Colnaghi (National Cancer Institute. Milan.…”

Use of Serum Tumor Markers in the Differential Diagnosis between Ovarian and Colorectal Adenocarcinomas

“…Efforts have been made to discriminate malignant from benign pelvic masses using monoclonal antibody-based tumor marker as says in serum [14][15][16][17][18][19] and in cyst fluid [20]. In general, elevated CA 125 serum levels are suggestive of malignancy.…”

Ovarian Carcinomas Express a Sperm Acrosomal Antigen, Defined by Monoclonal Antibody 9H8

“…9H8 dif fers from the others on the basis of a different expression pattern in normal tissues and mo lecular characteristics. The data available in the literature concerning 29 different anti bodies against ovarian carcinoma described by eight groups of authors [2][3][4][5][6][8][9][10] are dis cordant from 9H8 in respect of their reactivi ties with normal tissues. As all of these MAbs were confirmed to be unreactive with testis or fetal skin, we can conclude that the 9H8 anti gen is distinct from antigens described by the aforementioned authors.…”

Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences

“…while 0V-TLI6 was produced independently, using a completely different procedure by immunization with cyst fiuid from a pooriy differentiated ovarian carcinoma [9]. Both antibodies are of the IgGl subtype, and have been shown to have similar binding characteristics [10]. The affinity constants of both antibodies are virtually identical (approximately l-l-l 4x 10^ M"').…”

“…The following MoAbs directed to ovarian carcinomaassociated antigens were used: OV-TL3 [2], 0V-TL16 [9]. OV-TL30 [10] and M0vl8 [12]; kindly supplied by Dr M. Colnaghi (National Cancer Institute. Milan.…”

Use of Serum Tumor Markers in the Differential Diagnosis between Ovarian and Colorectal Adenocarcinomas

“…Efforts have been made to discriminate malignant from benign pelvic masses using monoclonal antibody-based tumor marker as says in serum [14][15][16][17][18][19] and in cyst fluid [20]. In general, elevated CA 125 serum levels are suggestive of malignancy.…”

Ovarian Carcinomas Express a Sperm Acrosomal Antigen, Defined by Monoclonal Antibody 9H8

“…9H8 dif fers from the others on the basis of a different expression pattern in normal tissues and mo lecular characteristics. The data available in the literature concerning 29 different anti bodies against ovarian carcinoma described by eight groups of authors [2][3][4][5][6][8][9][10] are dis cordant from 9H8 in respect of their reactivi ties with normal tissues. As all of these MAbs were confirmed to be unreactive with testis or fetal skin, we can conclude that the 9H8 anti gen is distinct from antigens described by the aforementioned authors.…”